 |
인쇄하기
취소
|
Dong-A to build 100 billion won biosimilar plant in Songdo
Korea’s large pharmaceutical company Dong-A Pharmaceutical reaffirmed its intention to advance into the biosimilar market, the company said in regulatory filing on Tuesday .
Biosimilars refer to subsequent versions of biopharmaceutical products following patent and exclusivity expiry on the products.
Last September of last year, Dong-A Pharm. signed a memorandum of understanding (MOU) wit...
Biosimilars refer to subsequent versions of biopharmaceutical products following patent and exclusivity expiry on the products.
Last September of last year, Dong-A Pharm. signed a memorandum of understanding (MOU) wit...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.